He L, et al. - Early human epidermal growth factor receptor 2 (HER2)-enriched breast cancer patients were examined for the overall survival (OS) following neoadjuvant trastuzumab (NAT) vs adjuvant trastuzumab (AT) treatment. Further, the difference in local-regional relapse (LRR) rate with this tumor and treatment was determined between women after mastectomy and women after breast-conserving therapy (BCT). Researchers analyzed 12 available clinical studies which contained 2,366 participants. NAT vs AT treatment provided an equivalent OS benefit in early-stage HER2-overexpression breast cancer patients. LRR rate was similar for patients who underwent mastectomy and BCT if they received anti-HER2 targeted therapy of trastuzumab, but patients who received mastectomy vs BCT had discernibly reduced LRR rate if they did not also receive trastuzumab treatment.